Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning
Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.
Compartir :

Myelofibrosis – Optimising myelofibrosis management with new and emerging therapies

Dr Jean-Jacques Kiladjian (Université Paris Cité, Paris, France), Dr Claire Harrison (Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai (ISMMS), New York, USA) and Prof Adam Mead (University of Oxford, Oxford, UK) discuss optimising myelofibrosis management with current and emerging therapies. 


The discussion covers a wide range of topics, including both current and emerging therapies, as well as available data and expert recommendations on risk stratification, molecular features, cytogenetics, and symptom burden. Additionally, the panellists explore suboptimal first-line treatment responses and strategies aimed at reducing transfusion dependence in patients with MF. They highlight the importance of multidisciplinary collaboration and individualised treatment plans to ensure the highest quality of care for MF patients. Patient assessment criteria are also discussed in depth. 

Myelofibrosis – Optimising myelofibrosis management with new and emerging therapies
Modulo
English
1 CME Points

Objetivos educativos

  1. Explain to a colleague available and emerging therapeutic strategies in best-practice management of patients with MF
  2. Appraise available and emerging clinical trial findings with novel agents for patients with MF
  3. Recognise the symptoms and patterns of suboptimal first-line treatment response in patients with MF, including treatment intolerance and treatment resistance
  4. Demonstrate strategies aimed at reducing transfusion dependence in patients with myelofibrosis 
  5. Formulate and implement strategies that target disease modification in patients with myelofibrosis.
  6. Effectively utilise the latest treatment guidelines in the management of patients with MF
  7. Demonstrate how to enhance care coordination for patients with MF